Effect of Telbivudine Versus Other Nucleos(t)ide Analogs on HBeAg Seroconversion and Other Outcomes in Patients with Chronic Hepatitis B: A Network Meta-Analysis

Conclusion At 1 year, telbivudine was superior to adefovir, entecavir and lamivudine in HBeAg seroconversion, and to entecavir and lamivudine in HBeAg loss. Telbivudine was also superior to lamivudine in ALT normalization and to adefovir and lamivudine in suppressing HBV DNA levels. Funding Novartis Pharma AG.

http://link.springer.com/10.1007/s12325-016-0305-x

Source: Advances in Therapy - February 26, 2016 Category: Drugs & Pharmacology Source Type: research